Overview
This interventional study will evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of ART6043 as monotherapy or in combination with olaparib.
Eligibility
Inclusion Criteria
- Age ≥21 years
- Smoke ≥5 CPD for ≥1 year
- Daily CC smoker
- Willing to switch to EC
- Exhaled CO ≥6 ppm
- Diagnosed with OUD
- Stable on bupropion treatment
- In good physical and mental health
- Able to use a smartphone
- Willing to participate in all study components
- Able to provide informed consent Exclusion Criteria
- Interested in quitting CC (contemplation stage of change)
- Use of EC on ≥4 of the past 30 days
- Use of other tobacco products (e.g., cigars, smokeless tobacco) on ≥9 days of the past 30 days
- Use of nicotine replacement therapy, smoking cessation medication, or a cessation attempt in the past 30 days
- Hypertension
- Medical condition that would contraindicate participation
- Meet DSM-V criteria for major depressive episode, psychotic episode, or manic episode
- Current suicidal ideation or suicide attempt in the past year
- Psychiatric hospitalization in the past year
- Contemplating pregnancy, currently pregnant, or breastfeeding
- Unable to speak and/or read English
